New long-term results from the CheckMate 238 clinical trial, published in the New England Journal of Medicine (NEJM Group), show sustained benefits of nivolumab (an immunotherapy drug that helps the immune system recognise and attack cancer cells) for patients with resected stage III or IV melanoma.
The study found longer recurrence-free survival with nivolumab compared to ipilimumab. For patients, this provides greater confidence that treatment can reduce the risk of melanoma returning years after surgery.
With outcomes followed for up to nine years, the study provides compelling evidence that nivolumab delivers longer recurrence-free survival compared to ipilimumab, offering patients greater confidence that treatment can reduce the risk of melanoma returning years after surgery.
Melanoma remains one of the most aggressive forms of skin cancer, with a high risk of recurrence even after successful surgical removal. Long-term data of this depth and duration are rare in oncology, making these findings particularly significant for both clinicians and patients navigating post-surgical treatment decisions.
Translating research into lasting patient impact
The clinical trial was conducted at the Cyril Gilbert Cancer Centre, Greenslopes Private Hospital, by the Gallipoli Medical Research Clinical Trials Unit, with Professor Victoria Atkinson (The University of Queensland) serving as a co-author on the publication.
GMR’s involvement in CheckMate 238 reflects its long-standing commitment to delivering high-quality, international clinical trials that directly influence clinical practice and patient care.
This study reinforces the value of immunotherapy not just in the short term, but over many years. For patients, this translates into greater certainty that their treatment continues to provide protection long after surgery.
A milestone for melanoma care
The publication of these results in a leading global medical journal underscores the impact of collaborative clinical research and the critical role of trial participants, investigators and clinical teams.
By contributing to trials such as CheckMate 238, GMR continues to help shape melanoma treatment standards worldwide, ensuring Australian patients have early access to cutting-edge therapies while advancing global understanding of cancer care.
GMR congratulates the investigators, clinical teams and trial participants whose dedication and collaboration have made this landmark research possible.
